Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22878225 | 0.88 | CHRM1 (0.41) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL2601120 | 0.86 | — | — | |
| SCHEMBL22878311 | 0.83 | CXCR3 (0.45) | EPHX2EPHX1SMN1; SMN2PIK3CD | |
| SCHEMBL329321 | 0.79 | CYP1A2 (0.52) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL4550276 | 0.77 | SMN1; SMN2 (0.52) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL1420780 | 0.77 | ACHE (0.31) | ALDH1A1 | |
| SCHEMBL11850495 | 0.77 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL83783 | 0.77 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL21325280 | 0.77 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL27183 | 0.77 | ALDH1A1 (0.56) | CYP1A2TDP1EPHX2EPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023230612-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2022012623-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-3283171-B1 | DERIVATIVES OF AMPHOTERICIN B | SFUNGA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2021004467-A1 | COMPOUND AS PORCUPINE INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2021-01-14 | — | — | WO | disclosed |
| WO-2019020041-A1 | COMPOUND AS ACC INHIBITOR AND USE THEREOF | 南京圣和药业股份有限公司 | 2019-01-31 | — | — | WO | disclosed |
| WO-2014004470-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20130165658-A1 | PROCESS FOR THE PREPARATION OF IODIDES | TECHNION R&D FOUNDATION LTD. (IL) | 2013-06-27 | — | — | US | disclosed |
| US-20130165658-A1 | PROCESS FOR THE PREPARATION OF IODIDES | TECHNION R&D FOUNDATION LTD. (IL) | 2013-06-27 | — | — | US | disclosed |
| EP-2125038-B1 | RADIOACTIVE PET AGENTS FOR IMAGING CCR5 IN VIVO | GE HEALTHCARE LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| EP-2402325-A2 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2399909-A1 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors | Array Biopharma, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011154953-A1 | PROCESS FOR THE PREPARATION OF IODIDES | TECHNION R&D FOUNDATION LTD. (IL) | 2011-12-15 | — | — | WO | disclosed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2008010934-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | CYP1A2 4612/4885TDP1 3110/4885EPHX2 1330/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CYP1A2 4616/4885TDP1 3598/4885EPHX2 2127/4885 |
| US-20130165658-A1 | PROCESS FOR THE PREPARATION OF IODIDES | NISCH, TPO, HDHD5 | CYP1A2 9/4885TDP1 3801/4885EPHX2 723/4885 |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | CYP1A2 1845/4885TDP1 2099/4885EPHX2 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.